Evox Therapeutics Ltd is a UK-based clinical trial company specializing in the discovery and development of novel therapeutics for neurological disorders. Established in March 2016, the company operates from its Medawar Centre facility located at Oxford’s renowned research hub. Evox focuses on identifying and validating new drug targets within areas like Alzheimer's disease, Parkinson's disease, and Lambert-Eaton Myelopathy. The core of Evox’s business model centers around preclinical studies, including animal models and initial human trials. The company actively monitors industry trends in neuroscience research, biotechnology advancements, and regulatory changes impacting the pharmaceutical sector. Evox maintains a robust competitor monitor to assess market dynamics and identify emerging therapeutic opportunities. Currently, Evox is classified as a ‘type’ of discovery company. They are estimated to have a workforce of approximately 30-40 employees. Their primary focus lies in translating fundamental research into viable clinical treatments. The company operates internationally, with a growing presence through strategic partnerships and collaborations within the European market. Currently listed under SIC code -72110 – Research and experimental development on biotechnology. Stock symbol: EVX

Evox Therapeutics Ltd is a UK-based clinical trial company specializing in the discovery and development of novel therapeutics for neurological disorders. Established in March 2016, the company operates from its Medawar Centre facility located at Oxford’s renowned research hub. Evox focuses on identifying and validating new drug targets within areas like Alzheimer's disease, Parkinson's disease, and Lambert-Eaton Myelopathy. The core of Evox’s business model centers around preclinical studies, including animal models and initial human trials. The company actively monitors industry trends in neuroscience research, biotechnology advancements, and regulatory changes impacting the pharmaceutical sector. Evox maintains a robust competitor monitor to assess market dynamics and identify emerging therapeutic opportunities. Currently, Evox is classified as a ‘type’ of discovery company. They are estimated to have a workforce of approximately 30-40 employees. Their primary focus lies in translating fundamental research into viable clinical treatments. The company operates internationally, with a growing presence through strategic partnerships and collaborations within the European market. Currently listed under SIC code -72110 – Research and experimental development on biotechnology. Stock symbol: EVX